TRIPCEE Clinical Monograph & Batch COA
Certified DCGI Formulation Literature (PDF)
TRIPCEE
Clobetasol 0.05% w/w , Neomycin 0.1% w/w , Miconazole 2% w/w
TRIPCEE (Clobetasol 0.05% w/w , Neomycin 0.1% w/w , Miconazole 2% w/w) is manufactured under strict WHO-GMP compliance for maximum bioavailability and therapeutic efficacy.
Clinical Pharmacology & Therapeutic Profile
Comprehensive therapeutic guidelines for medical practitioners and institutional procurement
Therapeutic Indications
Mechanism of Action (MOA)
The active pharmacological principles in TRIPCEE deliver targeted therapeutic action through standardized systemic bioavailability and verified pharmacodynamics.
As directed by the registered medical practitioner. Strictly adhere to full course duration.
Well tolerated under clinical supervision. Contraindicated in patients with hypersensitivity to active ingredients.
Store in a cool place below 25°C. Do not freeze. Replace cap tightly after use.
WHO-GMP Certified Purity
Manufactured in state-of-the-art HVAC controlled cleanrooms with 100% active ingredient bio-potency and analytical batch testing.
Alu-Alu Moisture Barrier
Superior barrier protection against tropical humidity, preventing physical degradation and guaranteeing 24-month stability.
Exclusive District Monopoly
Strict PCD franchise monopoly allocation ensuring zero price competition and complete territory protection for our partners.
Technical Product Specifications
Active Medical Composition
TRIPCEE features Clobetasol 0.05% w/w , Neomycin 0.1% w/w , Miconazole 2% w/w prepared to high pharmaceutical purity standards.
*Disclaimer: Formulations are intended solely for distribution to licensed practitioners, hospitals, and pharmacies. Dosage must adhere to medical advice.
Apply for Exclusive Marketing Rights of TRIPCEE
Check vacant territory availability in your state or district. Enjoy full marketing kit support, visual aids, and guaranteed zero competitor supply.
Questions Regarding TRIPCEE
What is the therapeutic indication and composition of TRIPCEE?
TRIPCEE contains Clobetasol 0.05% w/w , Neomycin 0.1% w/w , Miconazole 2% w/w indicated for Indicated for therapeutic management within specified clinical indications under qualified physician guidance. as formulated by Sygnus Biotech.
What packaging presentations are available for TRIPCEE?
TRIPCEE is supplied in tamper-evident 15g / 30g Laminated Aluminum Barrier Tube, engineered with barrier foil protection to ensure a 24 to 36 month shelf life.
Is monopoly PCD franchise territory available for TRIPCEE?
Yes, Sygnus Biotech grants exclusive district-wise monopoly marketing rights for TRIPCEE along with promotional visual aids, product cards, and marketing support.
What is the regulatory schedule and minimum order quantity (MOQ)?
TRIPCEE is categorized as Schedule H with an introductory PCD franchise MOQ of 100 units per batch.
Related Formulations in Cream & Ointment
View all Cream & Ointment →
VIVO+ GEL
Diclofenac Sodium 1% w/v + Linseed Oil 3% w/w + Methyl Salicylate 10% w/w +Capsaicin 0.025% w/w Menthol 5% w/w + Benzyl Alcohol 1% w/w
OXIDINE TOOTH PASTE
Rated 5 out of 5 based on 1 customer rating Pottasium Nitrate + Sodium Monofluorophosphate + Triclosan
ACNEGO ADVANCE CREAM
Hydroquinone 2% w/w + Tretinoin 0.025% w/w + Mometasone Furoate 0.1% w/w
DANTRAKSHA TOOTHPASTE
Borsali ext.(Mimesodhs Elengi) 0.20% , Babool ext.(Acacia Arebica) 0.60% , Mayuphal ext.(Quercus Infectoria) 0.20% , Punarnava ext(Boerhavia Diffusa) 0.10% , Amla ext.(Phyllanthus Emblica) 0.20% , Nagoda ext.(Vitex nigundo) 0.20% , Tumaru (Zanthoxylum Alatum 15.00%